Certara Inc
NASDAQ:CERT

Watchlist Manager
Certara Inc Logo
Certara Inc
NASDAQ:CERT
Watchlist
Price: 10.58 USD -1.21% Market Closed
Market Cap: 1.7B USD
Have any thoughts about
Certara Inc?
Write Note

Net Margin
Certara Inc

-8.3%
Current
-7%
Average
2.2%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-8.3%
=
Net Income
-31.1m
/
Revenue
372.8m

Net Margin Across Competitors

Country US
Market Cap 1.7B USD
Net Margin
-8%
Country US
Market Cap 36.3B USD
Net Margin
25%
Country US
Market Cap 31.3B USD
Net Margin
10%
Country AU
Market Cap 26.7B AUD
Net Margin
50%
Country US
Market Cap 10.7B USD
Net Margin
34%
Country US
Market Cap 6.3B USD
Net Margin
-6%
Country JP
Market Cap 934B JPY
Net Margin
16%
Country US
Market Cap 5.5B USD
Net Margin
4%
Country SE
Market Cap 53.5B SEK
Net Margin
25%
Country US
Market Cap 2.4B EUR
Net Margin
-4%
Country CN
Market Cap 16.2B CNY
Net Margin
11%
No Stocks Found

Certara Inc
Glance View

Market Cap
1.7B USD
Industry
Health Care

Certara Inc., founded in 2008, has emerged as a pivotal player in the realm of virtual drug development, leveraging its sophisticated model-based drug development technology to transform how pharmaceutical companies strategize and optimize drug discovery. The company's core strength lies in its comprehensive suite of biosimulation software and services, which predict how drugs behave in the human body. This revolutionary approach allows pharmaceutical companies to refine their drug development processes, increase efficiency, and reduce the time and cost associated with bringing new drugs to market. By providing insights into drug interactions, efficacy, and safety, Certara aids its clients in making informed decisions early in the development cycle, essentially becoming an indispensable ally in navigating the complex and costly landscape of drug development. Certara generates revenue primarily through software licensing and consulting services, establishing long-term partnerships with its diverse clientele, which includes over 1,850 companies worldwide, including prominent pharmaceutical giants and regulatory agencies. By embedding itself into the critical processes of drug development, Certara garners not just the upfront licensing fees but also ongoing consulting fees that allow pharmaceutical companies to fine-tune and optimize their drug development strategies continuously. As healthcare industries place increasing emphasis on precision medicine and personalized healthcare, Certara's role as a guide in these innovations becomes even more pronounced, ensuring its financial health and relevance in a highly competitive field. The company's growth reflects a keen understanding of its niche, capitalizing on its unique offerings to remain at the forefront of scientific innovation.

CERT Intrinsic Value
11.44 USD
Undervaluation 7%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-8.3%
=
Net Income
-31.1m
/
Revenue
372.8m
What is the Net Margin of Certara Inc?

Based on Certara Inc's most recent financial statements, the company has Net Margin of -8.3%.